Dr. Miden Melle Hanna honored in New York for innovation in kidney cancer treatment

NEW YORK — Dr. Miden Melle Hanna, a Syrian oncologist specializing in kidney and urinary tract cancers, has been honored in New York for her groundbreaking work on a novel medical device aimed at revolutionizing kidney cancer treatment.

The recognition, awarded by the Swedish-American Chamber of Commerce as part of the 2025 Nordic Acceleration Program, highlights Dr. Hanna’s dedication to advancing cancer care and improving treatment accessibility.

Raised in Jönköping, Sweden, and the daughter of acclaimed author Anna Melle, Dr. Hanna has spent years researching alternatives to traditional kidney cancer therapies. In 2017, she and a team of physicians introduced “Multi4”, an automated device that targets cancer cells, allowing treatment in the comfort of patients’ homes. This innovation offers a less invasive and more affordable option compared to conventional therapies.

In the US, kidney cancer treatments often exceed $140,000 per patient, requiring complex surgeries and lengthy recovery periods. Dr. Hanna’s device aims to alleviate these challenges by streamlining treatment, eliminating the need for hospitalization, and reducing recovery times.

Multi4 Medical, the company behind the technology, has earned numerous accolades for its innovative approach to oncology. The Swedish-American Chamber of Commerce’s recognition places Dr. Hanna and her team among nine leading institutions celebrated for advancing medical technology and patient care in 2025.

Dr. Hanna’s work represents a shift toward patient-centered innovation in cancer care, with the potential to transform outcomes for thousands of kidney cancer patients globally.